Literature DB >> 8687098

Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface.

O W Rokhlin1, T L Griebling, N V Karassina, M A Raines, M B Cohen.   

Abstract

Using specific ELISA kits, we investigated the secretion of cytokines in five human prostate carcinoma cell lines: ALVA 31, DU145, LNCaP, ND1 and PC3. Three of the five cell lines investigated secreted granulocyte-macrophage colony-stimulating factor (GM-CSF); GM-CSF was not identified in ALVA31 or LNCaP. In addition, we have shown that conditioned media of DU145, ND1 and PC3 stimulated proliferation of the GM-CSF-dependent cell line MO7e indicating that these cells secrete biologically active GM-CSF. By flow cytometric analysis we determined that all five cell lines expressed the alpha-subunit of the GM-CSF receptor on the cell surface but only ALVA31 expressed both the alpha- and beta-subunits of the GM-CSF receptor. Varying concentrations of GM-CSF did not stimulate the proliferation rate of any of the prostate carcinoma cell lines. Thus, there does not appear to be autocrine loop of GM-CSF-induced proliferation. However, the expression of E-cadherin and endoglin (CD105) was modulated under GM-CSF treatment in ALVA31. In addition, GM-CSF decreased the level of soluble CD44 in ND1. These results suggest that the GM-CSF receptor alpha-subunit may play a role in metabolic activity of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8687098

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Phase II trial of GM-CSF in advanced prostate cancer.

Authors:  R Dreicer; W A See; E A Klein
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 4.  Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.

Authors:  Palash Bhattacharya; Isadore Budnick; Medha Singh; Muthusamy Thiruppathi; Khaled Alharshawi; Hatem Elshabrawy; Mark J Holterman; Bellur S Prabhakar
Journal:  J Interferon Cytokine Res       Date:  2015-03-24       Impact factor: 2.607

5.  Magmas expression in neoplastic human prostate.

Authors:  Paul T Jubinsky; Mary K Short; George Mutema; Randal E Morris; Georgianne M Ciraolo; Maomi Li
Journal:  J Mol Histol       Date:  2005-02       Impact factor: 2.611

Review 6.  Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?

Authors:  Marouan Benna; Jean-Baptiste Guy; Claire Bosacki; Omar Jmour; Majed Ben Mrad; Oleksandr Ogorodniitchouk; Saïd Soltani; Meiling Lan; Elisabeth Daguenet; Benoîte Mery; Sandrine Sotton; Nicolas Magné; Alexis Vallard
Journal:  Br J Radiol       Date:  2020-02-04       Impact factor: 3.039

7.  Granulocyte macrophage colony-stimulating factor may modulate the post-transcription pathway of interleukin-6 expression in prostate carcinoma cells.

Authors:  Tae-Hyoung Kim; Seung-Young Oh; Young-Sun Kim; Mi-Kyung Lee; Hwa-Su Kim; Soon-Chul Myung
Journal:  J Korean Med Sci       Date:  2008-02       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.